Grünenthal Joins German Nucleic Acid Therapeutics Cluster

Pharmaceutical company Grünenthal announced its membership in the Cluster for Nucleic Acid Therapeutics Munich (CNATM), an innovation network focused on accelerating the development of new nucleic acid-based therapies. The collaboration aims to strengthen Grünenthal's expertise in discovering and developing genetic medicines, particularly for pain and neurological conditions.

By joining the CNATM, Grünenthal gains access to a network of leading German universities, research institutions, and biotech companies. This initiative is expected to bolster the company's in-house capabilities in oligonucleotide drug discovery, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), areas Grünenthal has been strategically investing in for the past few years.

A key objective for Grünenthal within the cluster is to deepen the understanding of oligonucleotide design, delivery methods, and cellular activity. The company is particularly interested in improving targeted delivery of siRNA to neuronal cells and related tissues relevant for conditions such as pain, epilepsy, and neurodegenerative disorders. This collaborative effort is anticipated to accelerate progress in this rapidly evolving field of medicine.

The CNATM brings together scientific expertise from institutions like Ludwig-Maximilians-Universität München and the Technical University of Munich, along with various biotech firms. Grünenthal anticipates that this partnership will foster new scientific insights and therapeutic concepts that can be advanced within the company or through external collaborations.